Test for Esophageal Reflux Licensed to Bayer by Wake Forest University Health Sciences
WINSTON-SALEM, N.C. – Patents covering a new procedure for diagnosing esophageal reflux disease developed by a Wake Forest University Health Sciences (WFUHS) otolaryngologist has been licensed to Bayer HealthCare’s Diagnostics Division by WFUHS.
The procedure, which detects the presence of human pepsin 3b in a patient’s saliva, was invented by Jamie Koufman, M.D., then professor of otolaryngology at Wake Forest University School of Medicine and director of WFUHS’s Center for Voice Disorders. She is now director of the Voice Institute of New York.
A test that is part of the procedure could be used in the offices of primary care physicians and avoid the need for more elaborate and expensive tests. Bayer will market the procedure.
“Most people associate heartburn with excess stomach acid, but it is the digestive enzyme pepsin (and not acid) bathing the lower area of the esophagus that causes the damage,” said Koufman. “For patients with severe esophagitis, the tissue in the esophagus is literally being self-digested.”
“Besides helping to diagnose gastroesophageal reflux disease, or ‘GERD,’ detecting pepsin in saliva also should help diagnose laryngopharyngeal reflux disease, the backflow of stomach contents into the throat,” she said. “Laryngopharyngeal reflux disease is even more difficult to diagnose than GERD. Scientific evidence points to aerosolized pepsin being drawn into the respiratory system as a common culprit of chronic cough, asthma, and even sinusitis.”
Dean Stell, associate director of the Office of Technology Asset Management, said, “Bayer is a world leader in point-of-care diagnostics and is well qualified to handle the next stage of development. That is the essence of technology transfer – working with our industrial counterparts who can develop technology in ways that we cannot.”
Stell added that the licensing step was “a milestone following 25 years of research, and lots of hard work by Dr. Koufman and the people on her team.”
He said the laboratory of Mark. O. Lively, Ph.D. “was vital in developing the proof of concept data that made this test commercially attractive.”
Lively and colleagues published a report on the work in the journal Laryngoscope in 2005.
Since 1981, Koufman has done pioneering research in gastric reflux, particularly that which affects the voice and breathing passages. She coined the term "laryngopharyngeal reflux" to describe the backflow of gastric contents into the throat.
Koufman said laryngopharyngeal reflux remains under-diagnosed and under-treated. “It is a frequent cause of hoarseness, a sensation of a lump in the throat, difficulty swallowing, choking episodes, and respiratory symptoms. It is sometimes difficult to diagnose because it is often silent, occurring without symptoms or heartburn.”
Koufman can be reached through the Voice Institute of New York web site, www.voiceinstituteny.com.
Media Contacts: Robert Conn, email@example.com, Shannon Koontz, firstname.lastname@example.org, or Karen Richardson, email@example.com, at (336) 716-4587.
Wake Forest University Baptist Medical Center is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university’s School of Medicine and its other related enterprises including the Piedmont Triad Research Park. The Medical School is ranked 4th in the Southeastern United States in revenues from its licensed intellectual property.
Media Relations Contacts: